Immunomodulatory Effects of Bifidobacterium bifidum BGN4 in Cyclophosphamide-induced Immunosuppressed Mice via Activation of NK Cells and Macrophages

This study examined whether a specific probiotic strain, Bifidobacterium bifidum BGN4, could boost immune function in both laboratory experiments and in mice whose immune systems had been chemically suppressed using cyclophosphamide — a drug commonly used in chemotherapy that causes significant immune decline. In cell-based experiments, the probiotic strongly activated two key frontline immune defenders: natural killer (NK) cells, which attack abnormal or infected cells, and macrophages, which engulf pathogens and coordinate inflammatory responses. When given orally to immunosuppressed mice, BGN4 helped restore body weight, organ size (spleen and thymus), and white blood cell counts that had dropped due to cyclophosphamide treatment. The probiotic also improved the ability of immune cells from the spleen to multiply in response to stimulation, and boosted NK cell killing activity in the suppressed animals. The researchers traced the macrophage effects to two well-known molecular switches — the MAPK and NF-κB signaling pathways — which control inflammation and immune activation. The overall picture is that BGN4 acts on multiple arms of immunity simultaneously, making it a candidate functional food ingredient for people undergoing immune-depleting treatments. While promising, the findings come from a mouse model and in vitro assays, so human clinical confirmation is still needed.

• In vitro, B. bifidum BGN4 significantly enhanced NK cell cytotoxicity against YAC-1 lymphoma target cells, indicating direct anti-tumor immune activation.
• BGN4-treated macrophages showed elevated nitric oxide production and increased secretion of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, alongside upregulated expression of phagocytosis-related genes Marco, Msr1, and Cd14.
• Macrophage activation was mechanistically linked to upregulation of both MAPK and NF-κB signaling pathways.
• Oral BGN4 administration in cyclophosphamide-immunosuppressed mice significantly mitigated reductions in body weight, spleen and thymus organ indices, and leukocyte counts.
• In vivo, BGN4 improved splenocyte proliferation under both unstimulated (basal) and mitogen-stimulated conditions, and restored NK cell cytotoxic activity in immunosuppressed animals.

The study used a dual in vitro / in vivo design. In vitro experiments assessed NK cell cytotoxicity against YAC-1 lymphoma cells and macrophage activation (nitric oxide, cytokine secretion, gene expression, and signaling pathway analysis) following B. bifidum BGN4 treatment. The in vivo component employed a cyclophosphamide-induced immunosuppression mouse model, with oral BGN4 administration; outcomes included body weight, spleen and thymus indices, leukocyte counts, splenocyte proliferation assays, and NK cell cytotoxicity. Specific group sizes, dosing regimens, and intervention duration are not detailed in the abstract but are reported in the full article published May 2026 in Probiotics and Antimicrobial Proteins.

As a mouse model study, the findings cannot be directly extrapolated to human immune responses, which differ substantially in NK cell biology, macrophage polarization dynamics, and responses to cyclophosphamide. The cyclophosphamide model mimics chemotherapy-induced immunosuppression but may not fully represent other causes of immune compromise such as aging, HIV, or primary immunodeficiencies. The abstract does not report effect sizes or dose-response data for the in vivo arm, making it difficult to assess the magnitude of recovery relative to healthy controls. The critical next steps would be dose-finding studies in larger animal models, mechanistic work on mucosal immune compartments specifically, and ultimately randomized controlled trials in immunocompromised human populations.

This study extends the broader corpus on probiotic-mediated immune modulation at the gut-immune interface, complementing work in the topic on how microbial agents reshape innate and adaptive immune signaling. It parallels [§143], which examines a quadruple probiotic mixture in an autoimmune hepatitis model and similarly invokes multi-pathway immune restoration, reinforcing the idea that specific probiotic strains can engage NF-κB-related and innate immune axes in disease contexts beyond the gut lumen itself. The BGN4 findings also extend [§153], which investigates probiotic intervention on allergic disease development and antibiotic-exposed infants, by demonstrating that probiotic immunomodulation operates through defined cellular effectors (NK cells, macrophages) rather than purely microbiota compositional shifts. A useful contrast is provided by [§150], an editorial framing gut microbiota as central to immune-inflammatory disease, which contextualizes why a single-strain probiotic acting on innate signaling pathways — as BGN4 does — represents a mechanistically tractable entry point into the broader microbiota-immunity axis. Together, these articles suggest a convergent theme: targeted microbial interventions can recalibrate host immunity through conserved innate signaling nodes, though the translation from animal models to clinical benefit remains the field's central unresolved challenge.

• Multi-omics Analysis Reveals the Protection of a Quadruple Probiotic Mixture in Experimental Autoimmune Hepatitis
  Both investigate probiotic restoration of immune function in animal disease models via overlapping innate immune pathways, allowing direct comparison of single-strain versus multi-strain probiotic efficacy.
• Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
  Examines probiotic immunomodulation in a distinct (allergic/antibiotic-exposed) context, providing a useful contrast population and outcome set to assess how broadly BGN4-type NK/macrophage mechanisms generalize.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  An editorial overview of gut microbiota roles in immune-inflammatory disease that provides the conceptual framework within which the BGN4 innate immune findings should be interpreted and positioned.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Focuses on Saccharomyces boulardii and intestinal barrier function, offering a mechanistic counterpoint on whether probiotic immune effects are primarily barrier-mediated or, as BGN4 suggests, directly cell-signaling-mediated.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Investigates a specific gut bacterium (Eubacterium rectale) modulating NF-κB signaling in IBD, sharing the NF-κB pathway mechanistic thread with BGN4's macrophage activation findings and enabling cross-strain pathway comparison.